Neuropharmacological profile of MD 780515, a new reversible inhibitor of type A monoamine oxidase.
Using several classical screening procedures, MD 780515, 3-[[4-[5-(methoxymethyl)-2-oxo-3-oxazolidinyl]phenoxy]methyl]- benzonitrile, was shown to possess potential antidepressant activity consistent with preferential and short-acting inhibition of type A monoamine oxidase. The doses effective in the tests for antidepressant activity were much lower than the lethal doses and were similar to or lower than those for reference drugs. MD 780515 showed some anti-convulsant action but had little effect on spontaneous or conditioned behaviour and was devoid of anticholinergic activity.
D000818:Animals; D000928:Antidepressive Agents; D001522:Behavior, Animal / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D000697:Central Nervous System Stimulants; D004347:Drug Interactions; D005260:Female; D006993:Hypnotics and Sedatives; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D010080:Oxazoles / Q000494:pharmacology* / Q000633:toxicity; D023303:Oxazolidinones; D051381:Rats; D011919:Rats, Inbred Strains
D000928:Antidepressive Agents; D000697:Central Nervous System Stimulants; D006993:Hypnotics and Sedatives; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D023303:Oxazolidinones; C026234:cimoxatone